ACD856, a novel positive allosteric modulator of Trk receptors, single ascending doses in healthy subjects: Safety and pharmacokinetics.

Purpose: AlzeCure Pharma AB is developing novel positive allosteric modulators of Trk-receptors for treatment of Alzheimer's disease, depression, other psychiatric conditions and other disorders where cognition is impaired. The preceding candidate drug ACD855 was shown to have a too long half-life i...

Descripción completa

Detalles Bibliográficos

Publicado en:	European Journal of Clinical Pharmacology Vol. 80; no. 5; pp. 717 - 728
Autores principales:	Nilsson, Boel, Bylund, Johan, Halldin, Magnus M., Rother, Matthias, Rein-Hedin, Erik, Önnestam, Kristin, Segerdahl, Märta
Formato:	research tables/charts randomized controlled trial Journal Article
Publicado:	Springer Nature May2024
Acceso en línea:	Ver este registro en EBSCOhost